[Immunoblastic lymphadenopathy occurring during treatment with carbamazepine. 2 cases].
Dysimmune lymphadenopathies during carbamazepine treatment. A report of two cases. We report on two cases of dysimmune lymphadenopathies with histological aspect of angio immunoblastic lymphadenopathy (AIL) developing after administration of carbamazepine. Clinical manifestations consisted of fever, erythroderma, generalized pruritus, facial edema, lymphadenopathy, liver enlargement. The two patients had anemia, hypogammaglobulinemia, impaired liver function and a negative Coomb's test. Lymphocyte stimulation test with carbamazepine in vitro was positive in both cases. Lymph node biopsy disclosed the angioimmunoblastic proliferation characteristic of AIL. After discontinuing carbamazepine, a complete remission was obtained.
D002220:Carbamazepine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000139:chemically induced* / Q000175:diagnosis; D008198:Lymph Nodes / Q000473:pathology; D008213:Lymphocyte Activation / Q000187:drug effects; D008875:Middle Aged; D011379:Prognosis
D002220:Carbamazepine
Lymphadénopathie dysimmunitaire survenant au cours d'un traitement par la carbamazépine. Deux observations.